Oesophageal cancer is an aggressive malignancy, with ∼45 0000 new cases globally each year ([@bib2]). In patients with potentially curative disease treatment usually comprises neoadjuvant therapy followed by surgery. Neoadjuvant therapy improves radical resection rates ([@bib18]), locoregional control ([@bib21]; [@bib4]) and treats distant micrometastases ([@bib27]). It has also been shown to increase survival in patients with locally advanced cancer ([@bib35]; [@bib8]; [@bib17]). Despite advances in neoadjuvant treatment, improved surgical technique and better patient selection, 5-year survival in these patients is still reported to range between 20 and 40% ([@bib32]; [@bib20]). Presently, in the UK adjuvant treatment remains only in use for those patients with oesophagogastric junctional tumours treated using the MAGIC regime ([@bib8]).

Currently, depth of tumour infiltration, and the presence and extent of lymph node metastases are the most important predictors of survival post surgery ([@bib29]). However, although patients who have no evidence of lymph node metastases after neoadjuvant therapy have a better survival, up to 40% go on to develop recurrent disease ([@bib24]; [@bib16]). Identification of other pathological features that may serve as indicators of poor outcome could permit increased accuracy in disease staging and consequently influence the use of adjuvant treatment.

The presence of venous invasion (VI), lymph vessel invasion (LI) and perineural invasion (PNI) have been increasingly identified as adverse prognostic markers in many malignancies ([@bib25]; [@bib31]; [@bib7]; [@bib5]). PNI represents a pathological process whereby tumour cells infiltrate into the nerve sheath and may lead to local spread as well as distant dissemination ([@bib25]; [@bib10]). Lymphovascular invasion indicates the presence of tumour cells within the lumen of veins and lymphatics, and is associated with high levels of recurrence ([@bib23]).

Hitherto, there has been no study reviewing the impact of these factors in patients that have received neoadjuvant therapy in oesophageal cancer. The aim of this study was to assess the incidence and prognostic significance of these three factors in a consecutive series of patients with cancer of the oesophagus or gastro-oesophageal junction (GOJ) who underwent neoadjuvant therapy followed by transthoracic oesophagectomy with two-field lymphadenectomy.

Patients and Methods
====================

Patient population
------------------

A prospectively maintained database of all patients with adenocarcinoma or squamous cell carcinoma of the oesophagus or oesophageal junction was reviewed. All patients were discussed by the multidisciplinary team and those who received neoadjuvant chemo(radiation) therapy followed by oesophagectomy with two-field lymphadenectomy in the Royal Victoria Infirmary in Newcastle-Upon-Tyne between January 2000 and September 2013 were included.

Pretreatment staging
--------------------

Initial staging comprised endoscopy with biopsy, endoscopic ultrasonography and a thoracoabdominal CT scan. A PET (CT) scan was not part of the initial staging, but was performed in some cases. Neoadjuvant treatment followed by oesophagectomy was indicated in patients deemed fit for surgery with histologically proven, locally advanced, resectable malignancy without distant metastases (cT1, N1--3, M0 or cT2--3, N0--3, M0) and/or had tumours of questionable resectability (cT4). Patients with metastases, unresectable tumours during exploratory surgery or macroscopically incomplete (palliative) resections (R2) and those who died in hospital after surgery were excluded. Current UICC TNM-7 was used to stage all patients [@bib34]).

Neoadjuvant treatment
---------------------

Multiple neoadjuvant regimens were used in the present study, determined by the standard of care, and recruiting trials at the time of each patient\'s treatment. Nearly all patients received chemotherapy (98.5%) compared with neoadjuvant chemoradiotherapy (1.5%), which was principally radiotherapy with cisplatin and fluoruracil.

Of those having neoadjuvant chemotherapy the majority (388 patients) received cisplatin and fluorouracil (CF -- 62.4%) as per the OEO2 regimen ([@bib1]) with 33% receiving epirubicin, cisplatin and either fluorouracil or capecitabine (ECF (6 patients)/ECX (124 patients) -- Magic regime ([@bib8])) and 1% received epirubicin, oxaliplatin and capecitabine (EOX) ([@bib9]).

Neoadjuvant chemoradiation was used in only seven (1.8%) patients, five received radiotherapy with carboplatin and paclitaxel, and the remaining two received other regimens.

Adjuvant ECC was planned in 100 (25.4%) of patients and 71 received this treatment.

Transthoracic oesophagectomy with two-field lymphadenectomy was carried out 4--6 weeks after completion of neoadjuvant therapy using a conventional approach as previously reported ([@bib14]).

Histopathological analysis
--------------------------

Whilst in theatre specimens are resected en bloc and each lymph node station is dissected by the surgeon and submitted in a separate container to the pathology department. Surgical specimens were fixed for 24 h in 10% formalin before sectioning. At least four blocks with tumour and adjacent benign peri-tumoural tissue were selected for histopathological evaluation and immunohistochemical staining. When there was no evidence of residual macroscopic tumour, specimens were widely sampled.

Histopathological reporting was carried out by a team of specialist gastrointestinal pathologists and followed a standardised format in line with the current guidelines as produced by the Royal College of Pathologists ([@bib26]): this included tumour type and differentiation, depth of tumour infiltration and degree of tumour regression as laid out by the Mandar criteria. Further, the number of nodes recovered, number of nodal metastases including the presence of extracapsular invasion and the presence of VI, PNI and LI were routinely recorded.

No specialised staining procedures were carried out to support the identification of lymphovascular infiltration.

Follow-up and definition of recurrence
--------------------------------------

All patients were followed until death or last follow-up (usually 10 years). All patients were seen at the outpatient clinic at 3- to 6-month intervals during the first 2 years, and every 6 months or annually thereafter. After 5 years, follow-up was on a yearly basis. Recurrence of disease was made on clinical grounds and confirmed either with CT scans or endoscopically.

Statistical analysis
--------------------

Statistical calculations were performed by SPSS software, version 22.0 (SPSS, Chicago, IL, USA). To compare categorical data, the *χ*^2^- or Fisher exact test was used. The Mann--Whitney *U*-test was used to compare continuous variables. Multivariate Cox-regression analysis was carried out to identify independent prognostic factors. All factors from the univariate analysis with a *P*-value \<0.10 were entered in this multivariate analysis. *P*-values \<0.05 (two-sided) were considered statistically significant.

Results
=======

Between January 2000 and September 2013, 425 patients underwent a transthoracic oesophagectomy after neoadjuvant therapy for mid-to-distal adenocarcinoma or squamous cell carcinoma of the oesophagus. In eight (1.9%) patients preoperatively detected metastases or tumour in-growth led to a palliative resection. Two (0.5%) patients underwent a salvage resection (after extended neoadjuvant therapy). Sixteen (3.8%) patients died due to postoperative complications and these patients were excluded. In five (1.2%) patients the presence (or absence) of either VI, LI and PNI or a combination was not reported in the pathology report and these patients were excluded.

Of the 394 included patients, almost 75% were male with a median age of 64 (23--80) years. The tumour was located in the mid-oesophagus in 43 (10.9%), in the distal oesophagus in 160 (40.6%) and at the GOJ in 191 patients (48.5%). The majority (302 patients, 76.6%) had an adenocarcinoma. More than three quarters (346 patients, 87.8%) had T3 tumours on EUS and only 37 patients (9.4%) did not have suspicion on lymph node metastases (cN0) ([Table 1](#tbl1){ref-type="table"}).

After transthoracic resection with two-field lymph node dissection, pathological examination revealed that 389 patients (98.0%) underwent a radical (R0) resection; microscopic tumour was left behind (R1 resection) in the other eight patients (2.0%) ([Table 2](#tbl2){ref-type="table"}). A median number of 33 (10--77) nodes was resected and identified. A total of 160 (40.6%) patients had no evidence of lymph node metastases (ypN0). There were 234 (59.4%) patients with positive nodes (ypN1--N3).

Venous invasion
---------------

The clinicopathological characteristics of the 245 (62%) patients with no VI and 149 (38%) patients with VI are summarised in [Table 2](#tbl2){ref-type="table"}. Significantly, VI was seen more frequently in patients who had more positive nodes resected (*P*\<0.001), a higher ypT stage (*P*\<0.001) or ypN stage (*P*\<0.001), and when lymph vessel (*P*\<0.001) or perineural invasion (*P*\<0.001) was present.

Lymph vessel invasion
---------------------

The clinicopathological characteristics of the 193 (49%) patients with no LI and 201 (51%) patients with LI are summarised in [Table 2](#tbl2){ref-type="table"}. LI was seen more frequently in patients with adenocarcinomas (*P*=0.002), more distal tumours (*P*\<0.001), in those who had more nodes (*P*=0.003) and positive nodes resected (*P*\<0.001), a higher ypT stage (*P*\<0.001) or ypN stage (*P*\<0.001), and when venous invasion (*P*\<0.001) or perineural invasion (*P*\<0.001) was present.

Perineural invasion
-------------------

The clinicopathological characteristics of the 191 (49%) patients with no PNI and 201 (51%) patients with PNI are summarised in [Table 2](#tbl2){ref-type="table"}. PNI was seen more frequently in patients with adenocarcinomas (*P*\<0.001), more distal tumours (*P*=0.041), a higher cT stage (*P*=0.033) as well as ypT stage (*P*\<0.001) or a higher cN stage (*P*=0.034) as well as ypN (*P*\<0.001) stage and when venous invasion (*P*\<0.001) or perineural invasion (*P*\<0.001) was present.

A total of 123 (31%) had no evidence of VI, LI or PNI. One out of three factors was present in 82 patients (21%). A combination of two out of three factors was present in 96 (24%), and 93 (24%) had presence of all three factors. A higher total score was significantly related with adenocarcinomas, more distal tumours, in those more with positive nodes resected, a higher ypT stage as well as ypN stage. Interestingly it was not associated with the clinical T and N stages of disease.

Further, there was a strong correlation between the number of factors involved and a higher Mandard score (*R*=0.539, *P*\<0.001).

Survival analysis
-----------------

Death irrespective of cause was regarded as a negative outcome in all cases. The Kaplan--Meier plots and results of the log-rank survival tests for the presence of one, two and three factors are shown in [Figure 1](#fig1){ref-type="fig"} as well as the survival curves when each of VI, LI and PNI are present. These demonstrate that the median overall survival was 170.8 months (95% confidence interval (CI): 68.9--272.8) if VI, LI and PNI were all absent. This fell to 40.9 months (95% CI: 19.9--61.9) when one factor was present, 27.1 months (95% CI: 22.8--31.4) when two factors were present and 16.3 months (95% CI: 10.3--22.4) when VI, LI and PNI were all present. Univariate analyses revealed that the presence of VI, LI and PNI, or a combination of these factors together with female gender, histology type, a microscopically non-radical resection (R1), higher ypT stage and higher ypN stage, as significant prognostic indicators for survival ([Table 3](#tbl3){ref-type="table"}). Multivariate analyses demonstrated that among these the presence of VI, LI and PNI, or a combination of these factors, female gender, histology type, a microscopically non-radical resection, higher ypT stage and higher ypN stage were independent prognostic factors ([Table 3](#tbl3){ref-type="table"}).

Adjuvant treatment
------------------

Adjuvant chemotherapy was planned in only 100 patients, with 71 of them receiving at least once course of postoperative chemotherapy. The median survival in patients treated with postoperative ECX was 44.4 months (95% CI: 27.6--61.1 months) in comparison with 18 months (95% CI: 0--44 months) for those who did not receive postoperative chemotherapy (*P*=0.072). Twenty-five patients had all three factors (VI, LI and PNI) and those that received postoperative chemotherapy had a significantly better survival than those that did not (21.6 months CI: 5.5--37.6 *vs* 10.5 months CI: 7.2--13.7).

Discussion
==========

Cancer of the oesophagus or GOJ is an aggressive malignancy. Currently, \>50% of patients treated with neoadjuvant therapy followed by surgery have disease recurrence. The present study indicates that in patients treated with neoadjuvant therapy followed by a transthoracic oesophagectomy with two-field lymphadenectomy, the presence of VI, LI and PNI, individually and in particular in combination are associated with significantly worse survival.

Patients with cancer of the oesophagus or GOJ who undergo surgery are staged by the TNM staging system (American Joint Committee on Cancer (AJCC) and Union Internationale Contre le Cancer [@bib34]). The current UICC TNM-7 has acknowledged the importance of the number of involved nodes by revising the N category from site-dependent staging to a numerically based classification ranging from N0 to N3.

In addition to these factors, the presence of VI, LI and or PNI in the tumour seems to be a surrogate for aggressive tumour behaviour and may serve as criteria for selecting patients for adjuvant therapy. Interestingly, the present study showed a survival benefit for those who had VI, LI and PNI and received postoperative chemotherapy according to the MAGIC protocol. Whilst this may be related to the chemotherapy received, it is possible that the improved survival may reflect a self-selecting group of patients who were better able to tolerate the additional treatment. Further studies looking are required, which focus on the value of adjuvant treatment in these high-risk patients. It is possible that the presence of VI, LI and or PNI may be used to stratify patient populations in future studies assessing the efficacy of adjuvant regimens. These factors may potentially have a preoperative prognostic use with assessment of these factors from endoscopic mucosal resection biopsies (EMR) potentially used to influence patient treatment ([@bib13]). Venous invasion, LI and PNI were not related to preoperative T and N staging, however, with all factors there was a strong relationship with higher ypT and ypN stages. Whilst this suggests a relationship with disease downstaging, particularly with regards to the Mandard scores, this needs further investigation. [@bib11]) demonstrated that staging after neoadjuvant treatment, rather than clinical staging determine survival in this cohort of patients. The results from this study suggest that assessing preoperative assessment of VI, LI and PNI on biopsies may help improve clinical staging, although future studies are required to see whether adequate assessment of these factors is possible on such biopsies.

The incidence of VI, LI and PNI is not well reported, which may be due to whether or not these factors were actively sought. [@bib36]) recently reported an incidence of 13% for VI, 5% for PNI and 35% for LI in a cohort who underwent unimodality surgical treatment. Other reports have suggested an incidence of PNI as high as 45% in squamous cell cancers of the oesophagus and 54% in all oesophageal subtypes ([@bib37]; [@bib6]) and LVI of up to 48% ([@bib33]) and VI of up to 56% ([@bib37]). At our institution the presence or absence of these factors was recorded with only 1.2% of reports failing to comment on these factors. The findings from this study have indicated a much higher level of presence of each of these factors, which may have a significant bearing on predicting a patient\'s prognosis and may be due to the use of a formalised pathology pro forma. This study, however, has not differentiated between intra- and extramural invasions as a factor.

Presence of VI, LI and PNI in this study conveys similar prognostic outcomes to respective 'N\' staging with a single factor being approximately equivalent to N1, through to the presence of all three factors equating to a similar prognosis as N3. Although it would be beneficial to determine the significance of each of these factors and whether any have greater importance, separate sub-analysis in this study showed all three factors were independently related to survival, and thus all should be assessed. The suggestion of VI, PNI and LI as adverse prognostic factors has been well described in other cancers. Lymphovascular involvement has been found to correlate with TNM disease stage in breast, endometrial, gastric and colonic cancers ([@bib31]; [@bib7]; [@bib15]; [@bib23]) and similarly PNI has been recorded as a poor prognostic factor in gastric, prostate, colonic and pancreatic cancers ([@bib28]; [@bib12]; [@bib3]; [@bib22]). The prognostic significance of VI remains unclear with a number of studies suggesting that it has independent prognostic value ([@bib33]; [@bib30]) although this may be cancer subtype specific ([@bib36]), whilst others have found that VI does not have a prognostic impact ([@bib19]; [@bib38]).

In conclusion, these findings suggest the presence of VI, LI and PNI after neoadjuvant therapy followed by oesophagectomy may have an important prognostic role. Their presence should be incorporated in a standardised pathology report as they provide additional information for identifying patients at high risk of disease recurrence who may be candidates for adjuvant therapies.
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###### Pretreatment clinicopathologic characteristics of patients with cancer of the oesophagus or GOJ who underwent neoadjuvant chemo (radiation) therapy followed by transthoracic oesophagectomy with two-field lymphadenectomy

                                                                ***N***               
  ------------------------------------------------------ --------------------- -------------
  Number of patients                                              394                 
  Age[a](#t1-fn2){ref-type="fn"}                          64.0 (23.37--79.85)         
  Male                                                        293 (74.4%)             
  **Histology**                                                                
  Adenocarcinoma                                              302 (76.6%)             
  Squamous cell                                               92 (23.4%)              
  **Tumour location**                                                          
  Mid-oesophagus                                              43 (10.9%)              
  Distal oesophagus                                           160 (40.6%)             
  GOJ                                                         191 (48.5%)             
  Radicality of surgery RO:R1                              386 (98%): 8 (2%)          
  Number of resected nodes                                    33 (10--77)             
  Number of positive nodes                                     1 (0--35)              
  **Pretreatment clinical T stage/post-treatment ypT**                         
  cTx/ypT0 3 (0.8%)                                            17 (4.3%)              
  cT1/ypT1                                                     3 (0.8%)         48 (12.2%)
  cT2/ypT2                                                     21 (5.3%)         75 (19%)
  cT3/ypT3                                                    346 (87.8%)       238 (60.4%)
  cT4/ypT4                                                     21 (5.3%)         16 (4.1%)
  **Pretreatment clinical N stage/post-treatment ypN**                         
  cN0/ypN0                                                     37 (9.4%)        160 (40.6%)
  cN1/ypN1                                                    274 (69.5%)       83 (21.1%)
  cN2/ypN2                                                    65 (16.5%)        80 (20.3%)
  cN3/ypN3                                                     15 (3.8%)         71 (18%)
  cNx                                                          3 (0.8%)               

Abbreviations: GOJ=gastro-oesophageal junction; R0=microscopically radical resection; R1=microscopically tumour left behind.

Values depicted are median (range).

###### Characteristics of patients and their histology in relation to the presence of each of VI, LI and PNI

                                **VI not present**   **VI present**   ***P*****-value**   **LI not present**   **LI present**   ***P*****-value**   **PNI not present**   **PNI present**   ***P-*****value**
  ---------------------------- -------------------- ---------------- ------------------- -------------------- ---------------- ------------------- --------------------- ----------------- -------------------
  Number of patients               245 (62.2%)        149 (37.8%)                             193 (49%)          201 (51%)                              191 (48.5%)         203 (51.5%)              
  Age                             63.5 (23--79)       65.3(33--80)          0.165           64.22 (34--79)      64 (23--80)           0.165            64.3 (23--79)       63.9 (33--80)          0.286
  Male                              179 (61%)          114 (39%)                             138 (47.1%)        155 (52.9%)                             140 (47.8%)         153 (52.2%)              
  Female                            66 (65.3%)         35 (34.7%)           0.447             55 (54.4%)         46 (45.6%)           0.202             51 (50.5%)          50 (49.5%)            0.638
  **Histology**                                                                                                                                                                            
  Adenocarcinoma                   183 (60.6%)        119 (39.4%)                            135 (44.7%)        167 (55.3%)                              133 (44%)           169 (56%)               
  Squamous cell carcinoma           62 (67.4%)         30 (32.6%)           0.239              58 (63%)           34 (37%)          **0.002**            58 (63%)            34 (37%)           **0.001**
  **Tumour location**                                                                                                                                                                      
  Mid oesophagus                    29 (67.4%)         14 (32.6%)                             32 (74.4%)         11 (25.6%)                             27 (62.8%)          16 (37.2%)               
  Lower oesophagus                 105 (65.6%)         55 (34.4%)                             86 (53.8%)         74 (46.2%)                             82 (51.3%)          78 (48.7%)               
  GOJ                              111 (58.1%)         80 (41.9%)           0.265             75 (39.3%)        116 (60.7%)        **\<0.001**          82 (42.9%)          109 (57.1%)         **0.041**
  **Pretreatment T stage**                                                                                                                                                                 
  T1                                2 (66.7%)          1 (33.3%)                              2 (66.7%)          1 (33.3%)                               2 (66.7%)           1 (33.3%)               
  T2                                14 (66.7%)         7 (33.3%)                              13 (61.9%)         8 (38.1%)                              17 (81.0%)            4 (19%)                
  T3                               213 (61.6%)        133 (38.4%)                            168 (48.6%)        178 (51.4%)                             161 (45.2%)         185 (54.8%)              
  T4                                13 (61.9%)         8 (38.1%)                              7 (33.3%)          14 (66.7%)                              9 (42.9%)          12 (57.1%)               
  Tx                                 3 (100%)            0 (0%)             0.72               3 (100%)            0 (0%)             0.137              2 (66.7%)           1 (33.3%)          **0.033**
  **Pretreatment N Stage**                                                                                                                                                                 
  N0                                25 (67.6%)         12 (32.4%)                             17 (45.9%)         20 (54.1%)                             11 (29.7%)          26 (70.3%)               
  N1                               171 (62.4%)        103 (37.6%)                            129 (47.1%)        145 (52.9%)                             132 (48.2%)         142 (51.8%)              
  N2                                 39 (60%)           26 (40%)                              35 (53.8%)         30 (46.2%)                             37 (56.9%)          28 (43.1%)               
  N3                                8 (53.3%)          7 (46.7%)                              10 (66.7%)         5 (33.3%)                               8 (53.3%)           7 (46.7%)               
  Nx                                2 (66.7%)          1 (33.3%)            0.891             2 (66.7%)           1 (33.3)            0.493              3 (100%)             0 (0%)            **0.034**
  **Radicality**                                                                                                                                                                           
  R0                               240 (62.2%)        146 (37.8%)                             189 (49%)          197 (51%)                               189 (49%)           197 (51%)               
  R1                                5 (62.5%)          3 (37.5%)            0.985              4 (50%)            4 (50%)               1                 2 (25%)             6 (75%)               1
  Number of resected nodes         33 (11--77)        32 (10--64)           0.787            31 (11--77)        35 (10--75)         **0.003**           32 (22--77)         33 (10--72)           0.532
  Number of positive nodes          0 (0--13)          3 (0--35)         **\<0.001**          0 (0--12)           3 (0.35)         **\<0.001**           0 (0--18)           3 (0--35)            0.532
  **Post-treatment T stage**                                                                                                                                                               
  ypT0                              17 (100%)            0 (0%)                               17 (100%)            0 (0%)                                17 (100%)            0 (0%)                 
  ypT1                              41 (85.4%)         7 (14.6%)                              40 (83.3%)         8 (16.7%)                              47 (97.9%)           1 (2.1%)                
  ypT2                              55 (73.3%)         20 (26.7%)                             41 (54.7%)         34 (45.3%)                             55 (73.3%)          20 (26.7%)               
  ypT3                             128 (53.8%)        110 (46.2%)                             90 (37.8%)        148 (62.2%)                             71 (29.8%)          167 (70.2%)              
  ypT4                               4 (25%)            12 (75%)         **\<0.001**          5 (31.3%)          11 (68.7%)        **\<0.001**           1 (6.3%)           15 (93.7%)         **\<0.001**
  **Post-treatment N stage**                                                                                                                                                               
  ypN0                             131 (81.9%)         29 (18.1%)                            119 (74.4%)         41 (25.6%)                             116 (72.5%)         44 (27.5%)               
  ypN1                              54 (65.1%)         29 (34.9%)                             43 (51.8%)         40 (48.2%)                             42 (50.6%)          41 (49.4%)               
  ypN2                               36 (45%)           44 (55%)                              21 (26.3%)         59 (73.7%)                              24 (30%)            56 (70%)                
  ypN3                              24 (33.8%)         47 (66.2%)        **\<0.001**          10 (14.1%)         61 (85.9%)        **\<0.001**           9 (12.7%)          62 (87.3%)         **\<0.001**
  LI present                        83 (41.3%)        118 (58.7%)        **\<0.001**              NA                 NA                                 54 (26.9%)          147 (73.3%)        **\<0.001**
  PNI present                       93 (45.8%)        110 (54.2%)        **\<0.001**          56 (27.6%)        147 (82.4%)        **\<0.001**              NA                  NA                   
  VI present                            NA                 NA                                 31 (20.8%)        118 (79.2%)        **\<0.001**          39 (26.2%)          110 (73.8%)        **\<0.001**

Abbreviations: GOJ=gastro-oesophageal junction; LI=lymph vessel invasion; PNI=perineural invasion; VI=venous invasion. The bold entries are those that are statistically significant

###### Uni- and multivariate analysis of prognostic factors for disease-free survival in patients with cancer of the oesophagus or GOJ who underwent neoadjuvant chemoradiation therapy followed by a transthoracic oesophagectomy

                                        **Median survival (95% confidence interval)**   ***P*-value univariate**[a](#t3-fn2){ref-type="fn"}   ***P*-value multivariate**
  ------------------------------------ ----------------------------------------------- ----------------------------------------------------- ----------------------------
  **Age**                                                                                                                                    
  \<65                                              37.98 (29.09--46.87)                                       0.676                                     ---
  ⩾65                                               40.90 (15.20--66.60)                                                                                   
  **Sex**                                                                                                                                    
  Male                                              97.31 (57.8--136.83)                                     **0.005**                                **0.006**
  Female                                            32.89 (26.54--39.24)                                                                                   
  **Histology type**                                                                                                                         
  Adeno                                             35.29 (27.22--43.35)                                       0.054                                  **0.030**
  Squamous cell                                     65.61 (28.39--102.83)                                                                                  
  **Tumour location**                                                                                                                        
  Mid oesophagus                                    98.10 (35.12--161.09)                                      0.145                                     ---
  Distal oesophagus                                 37.98 (21.17--54.80)                                                                                   
  GOJ                                               34.43 (24.32--44.54)                                                                                   
  **Radicality**                                                                                                                             
  R0                                                 40.9 (26.60--55.21)                                     **0.001**                                **0.002**
  R1                                                12.62 (11.86--13.38)                                                                                   
  **Post-treatment T stage (ypT)**                                                                                                           
  ypT0                                             150.68 (111.72--182.66)                                  **\<0.001**                                 0.150
  ypT1                                              97.31 (77.91--116.72)                                                                                  
  YpT2                                              78.48 (66.39--90.57)                                                                                   
  ypT3                                              28.55 (24.01--33.09)                                                                                   
  ypT4                                               7.52 (3.09--11.96)                                                                                    
  **Post-treatment N stage (ypN)**                                                                                                           
  ypN0                                             170.84 (72.27--269.41)                                   **\<0.001**                              **\<0.001**
  ypN1                                              66.07(15.94--116.20)                                                                                   
  ypN2                                              24.25 (17.03--31.46)                                                                                   
  ypN3                                               13.21 (9.93--16.49)                                                                                   
  **The presence of VI, LI and PNI**                                                                                                         
  No presence                                      170.84 (69.94--272.75)                                   **\<0.001**                               **0.007**
  One factor present                                40.90 (19.95--61.86)                                                                                   
  Two factors present                               27.11 (22.76--31.45)                                                                                   
  Three factors present                             16.33 (10.27--22.39)                                                                                   

Abbreviations: GOJ=gastro-oesophageal junction; LI=lymph vessel invasion; PNI=perineural invasion; R0=microscopically radical resection; R1=microscopically tumour left behind; VI=venous invasion. The bold entries are those that are statistically significant.

Log-rank test.
